Lantheus Holdings reported second quarter 2026 financial results with worldwide revenue of $388.2 million, a 2.7% increase from the prior year period. GAAP fully diluted earnings per share were $1.11, while adjusted fully diluted EPS was $1.55. The company suspended its full-year 2026 financial guidance and will not host an earnings conference call due to pending M&A activity. On August 3, 2026, Lantheus entered into a definitive agreement to merge with Curium in an all-cash transaction valued at up to approximately $8.0 billion. Under the deal, shareholders will receive $102.50 per share plus Contingent Value Rights providing for up to $12.00 per share based on commercial milestones through 2030. The combined entity aims to create a radiopharmaceutical company spanning diagnostics and therapeutics across more than 70 countries. Lantheus is a leading radiopharmaceutical-focused company delivering diagnostic and therapeutic solutions.

Lantheus Holdings, Inc. entered into a definitive Agreement and Plan of Merger with Curium US Holdings LLC on August 3, 2026, pursuant to which Lantheus will be acquired in an all-cash transaction valued at $102.50 per share. The consideration includes one contractual contingent value right (CVR) per share, entitling holders to receive up to $12.00 in cash upon the achievement of specific commercial milestones for the Global Prostate Cancer Diagnostics, Global Neurology Diagnostics, and Global DEFINITY franchises. The merger is not subject to any financing condition, with Parent having secured equity and debt commitments. Closing is conditioned on stockholder approval, regulatory clearances including Hart-Scott-Rodino expiration, and the absence of a Material Adverse Effect. If terminated under specific circumstances, Curium must pay Lantheus a $385 million termination fee or a $100 million regulatory fee. The company operates in the medical diagnostics industry, specializing in radiopharmaceuticals for oncology and neurology.